Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 1;323(4):H702-H720.
doi: 10.1152/ajpheart.00231.2022. Epub 2022 Aug 5.

Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress

Jean C Bikomeye  1 , Janée D Terwoord  2   3 , Janine H Santos  4 , Andreas M Beyer  2   5   6
Affiliations
Review

Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress

Jean C Bikomeye et al. Am J Physiol Heart Circ Physiol. .

Abstract

Many anticancer therapies (CTx) have cardiotoxic side effects that limit their therapeutic potential and cause long-term cardiovascular complications in cancer survivors. This has given rise to the field of cardio-oncology, which recognizes the need for basic, translational, and clinical research focused on understanding the complex signaling events that drive CTx-induced cardiovascular toxicity. Several CTx agents cause mitochondrial damage in the form of mitochondrial DNA deletions, mutations, and suppression of respiratory function and ATP production. In this review, we provide a brief overview of the cardiovascular complications of clinically used CTx agents and discuss current knowledge of local and systemic secondary signaling events that arise in response to mitochondrial stress/damage. Mitochondrial oxidative stress has long been recognized as a contributor to CTx-induced cardiotoxicity; thus, we focus on emerging roles for mitochondria in epigenetic regulation, innate immunity, and signaling via noncoding RNAs and mitochondrial hormones. Because data exploring mitochondrial secondary signaling in the context of cardio-oncology are limited, we also draw upon clinical and preclinical studies, which have examined these pathways in other relevant pathologies.

Keywords: DAMPs; cardio-oncology; cardiotoxicity; chemotherapy; mitochondria.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest, financial or otherwise, are declared by the authors.

Figures

Figure 1.
Figure 1.
Graphical illustration of selected anticancer therapy (CTx) drugs illustrating their mitochondrial pathophysiological signaling pathways and some of the associated cardiotoxic outcomes. CTx agents work through different mechanisms and induce mitochondrial dysfunction through various pathophysiological pathways. This is graphical illustration of complex pathogenic pathways using selected examples from literature identified in our article. It is not meant to be an exhaustive depiction of all existing pathways but rather presents some key examples. Image created with Rawgraphs.io and published with permission. ETC, electron transport chain; MACE, major adverse cardiovascular events; ROS, reactive oxygen species; TKI, tyrosine kinase inhibitor.
Figure 2.
Figure 2.
Anticancer therapy (CTx) alters intracellular mitochondrial signaling. Several CTx agents induce mitochondrial dysfunction by promoting mitochondrial DNA (mtDNA) damage, suppressing mitochondrial metabolism, altering mitochondrial Ca2+ homeostasis, increasing production of reactive oxygen species (ROS), altering mitochondrial-nuclear communication, and/or inducing epigenetic and transcriptional remodeling. Mitochondria also play a role in CTx-induced apoptosis through release of cytochrome-c (Cyt c) and second mitochondria-derived activator of caspases (SMAC) and activation of apoptosomes. Nucleic acids in the cytosol, including mtRNA and mtDNA, activate innate immune cascades that ultimately promote inflammation. Image created with Biorender.com and published with permission. AIM2, absent-in melanoma 2; cGAS, GMP-AMP synthase; IRF3, interferon regulatory factor 3; RIG-I, retinoic acid-inducible gene I; STING, stimulator of interferon genes.
Figure 3.
Figure 3.
Systemic mitochondrial signaling may promote cardiovascular inflammation following anticancer therapy (CTx). CTx-induced cellular stress and death promote the release of damage-associated molecular patterns (DAMPs). DAMPs released from mitochondria include cell-free mitochondrial DNA (mtDNA), ATP, formyl peptides, and mitochondrial membrane fractions, among others. Circulating mitochondrial DAMPs are recognized by pattern recognition receptors of the innate immune system, including Toll-like receptors (TLRs), purinergic receptors, formyl peptide receptors (FPRs), and nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs). Activation of innate immune receptors on immune cells, cardiomyocytes, and vascular cells promotes cardiovascular inflammation that may play a role in CTx-induced cardiotoxicity. Image created with Biorender.com and published with permission.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bikomeye JC, Beyer AM, Kwarteng JL, Beyer KMM. Greenspace, inflammation, cardiovascular health, and cancer: a review and conceptual framework for greenspace in cardio-oncology research. Int J Environ Res Public Health 19: 2426, 2022. doi:10.3390/ijerph19042426. - DOI - PMC - PubMed
    1. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Global Health, Committee on Global Health and the Future of the United States. Global Health and the Future Role of the United States. Washington, DC: National Academies Press, 2017. - PubMed
    1. Bertero E, Ameri P, Maack C. Bidirectional relationship between cancer and heart failure: old and new issues in cardio-oncology. Card Fail Rev 5: 106–111, 2019. doi:10.15420/cfr.2019.1.2. - DOI - PMC - PubMed
    1. Gabani M, Castañeda D, Nguyen QM, Choi S-K, Chen C, Mapara A, Kassan A, Gonzalez AA, Khataei T, Ait-Aissa K, Kassan M. Association of cardiotoxicity with doxorubicin and trastuzumab: a double-edged sword in chemotherapy. Cureus 13: e18194, 2021. doi:10.7759/cureus.18194. - DOI - PMC - PubMed
    1. Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat 188: 21–36, 2021. doi:10.1007/s10549-021-06280-x. - DOI - PubMed

Publication types